CN113368205A - 一种治疗胃癌的中药组合物 - Google Patents
一种治疗胃癌的中药组合物 Download PDFInfo
- Publication number
- CN113368205A CN113368205A CN202110746322.0A CN202110746322A CN113368205A CN 113368205 A CN113368205 A CN 113368205A CN 202110746322 A CN202110746322 A CN 202110746322A CN 113368205 A CN113368205 A CN 113368205A
- Authority
- CN
- China
- Prior art keywords
- parts
- gastric cancer
- traditional chinese
- chinese medicine
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 49
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 49
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 49
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 239000000203 mixture Substances 0.000 title claims description 13
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 14
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 14
- 235000011201 Ginkgo Nutrition 0.000 claims abstract description 13
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 13
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 13
- 235000014066 European mistletoe Nutrition 0.000 claims abstract description 8
- 244000152640 Rhipsalis cassutha Species 0.000 claims abstract description 8
- 235000012300 Rhipsalis cassutha Nutrition 0.000 claims abstract description 8
- JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims abstract description 7
- JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000010081 allicin Nutrition 0.000 claims abstract description 7
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 6
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 6
- 244000248416 Fagopyrum cymosum Species 0.000 claims abstract description 6
- 244000261559 Smilax china Species 0.000 claims abstract description 6
- 235000000485 Smilax china Nutrition 0.000 claims abstract description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 claims abstract description 5
- 244000247747 Coptis groenlandica Species 0.000 claims abstract description 5
- 240000009022 Smilax rotundifolia Species 0.000 claims abstract description 5
- 235000003205 Smilax rotundifolia Nutrition 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000006187 pill Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 244000130270 Fagopyrum tataricum Species 0.000 claims description 2
- 235000014693 Fagopyrum tataricum Nutrition 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 230000006907 apoptotic process Effects 0.000 abstract description 10
- 238000011282 treatment Methods 0.000 abstract description 8
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 3
- 230000036737 immune function Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 25
- 206010028980 Neoplasm Diseases 0.000 description 7
- 238000002512 chemotherapy Methods 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 206010027476 Metastases Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000001959 radiotherapy Methods 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- VCCRNZQBSJXYJD-UHFFFAOYSA-N galangin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=CC=C1 VCCRNZQBSJXYJD-UHFFFAOYSA-N 0.000 description 2
- 230000009950 gastric cancer growth Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000605422 Asparagus asparagoides Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- 230000004668 G2/M phase Effects 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 244000265736 Nelumbo pentapetala Species 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 231100000005 chromosome aberration Toxicity 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- CIPSYTVGZURWPT-UHFFFAOYSA-N galangin Natural products OC1=C(Oc2cc(O)c(O)cc2C1=O)c3ccccc3 CIPSYTVGZURWPT-UHFFFAOYSA-N 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000004065 mitochondrial dysfunction Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000024121 nodulation Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- SUYJZKRQHBQNCA-UHFFFAOYSA-N pinobanksin Natural products O1C2=CC(O)=CC(O)=C2C(=O)C(O)C1C1=CC=CC=C1 SUYJZKRQHBQNCA-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗胃癌的中药，是由下列重量份的原料药组成：大蒜素0.05～0.1重量份；高良姜、黄莲3～6重量份；山柰、银杏叶4.5～9重量份；连翘7～15重量份；野菊花9～18重量份；红芪、菝葜、白果槲寄生15～30重量份；金荞麦根20～40重量份。本发明可以增强机体免疫功能，杀死胃癌细胞、诱导胃癌细胞分化和凋亡、防止胃癌细胞转移，减轻患者痛苦、提高病人生存质量，提高了胃癌患者的治愈率，具有治疗效果显著、无毒副作用等特点。
Description
技术领域
本发明涉及中药的制备领域，特别是涉及一种治疗胃癌的中药组合物。
背景技术
胃癌是起源于胃黏膜上皮的恶性肿瘤，在我国各种恶性肿瘤中发病率居首位，胃癌发病有明显的地域性差别，在我国的西北与东部沿海地区胃癌发病率比南方地区明显为高。
传统治疗方法有种种缺陷，手术治疗能将肿瘤切除，但是，手术风险高，手术对人体创伤大，使患者免疫力降低，对疾病抵抗力下降，手术为局部治疗手段，只适用于早期且身体状况能够耐受的患者；手术切除不能除根，会直接导致胃癌细胞扩散。
化疗药物几乎都是细胞毒性药物，在杀死肿瘤细胞的同时，对人体的正常细胞有一定的毒副作用，尤其是对分裂、增殖、比较快的细胞如骨髓造血细胞、胃肠道粘膜上皮细胞等。化疗会缩短患者生存时间且部分肿瘤对药物不敏感，化疗不可能彻底杀死体内所有胃癌细胞，在一定的时间内胃癌细胞还会复发或转移。
放射治疗常作为一种辅助治疗或姑息治疗手段。放射治疗在破坏肿瘤的同时，正常组织细胞也会受到一定的损害，超过这一限制剂量就会对组织产生不可逆损害，而且，放射治疗还可能降低机体的免疫力。放射的剂量是经过理论计算来完成，难以与实际相符合，只有小于 2cm 的肿瘤才能一次性完全破坏。
发明内容
本发明的目的在于改进已有技术的不足而提供一种治疗胃癌的中药组合物，使其可以有效的抵抗胃癌细胞、防止胃癌细胞转移，提高了胃癌患者的治愈率，具有治疗效果显著、无毒副作用等特点。
本发明提供了一种治疗胃癌的中药组合物，该中药组合物包括：大蒜素0.05～0.1重量份；高良姜、黄莲3～6重量份；山柰、银杏叶4.5～9重量份；连翘7～15重量份；野菊花9～18重量份；红芪、菝葜、白果槲寄生15～30重量份；金荞麦根20～40重量份。
在一个优选的实施方案中，所述治疗胃癌的中药组合物由下列重量份的原料药组成：大蒜素0.1重量份；高良姜、黄莲6重量份；山柰、银杏叶9重量份；连翘15重量份；野菊花18重量份；红芪、菝葜、白果槲寄生30重量份；金荞麦根40重量份。
本发明还提供一种治疗胃癌的口服制剂，该口服制剂由上述中药组合物制成。
其中，高良姜：辛，热。归脾、胃经。主治温胃散寒，消食止痛。高良姜素对胃癌细胞有显著的增殖抑制作用,高良姜素通过干扰细胞周期循环和介导线粒体功能障碍,诱导细胞凋亡,从而抑制胃癌SGC-7901细胞的生长。
金荞麦根：微辛、涩，凉。归肺经。清热解毒，排脓祛瘀。金荞麦根根能明显抑制癌细胞内的核酸代谢，对胃癌杀死率为78.2%。
连翘：苦，微寒。归肺、心、小肠经。清热解毒，消肿散结。
连翘提取物体外能明显抑制胃癌细胞增殖并诱导其发生凋亡,具有有显著抗癌活性。
山柰：味辛，温。温中化湿，行气止痛。山奈能促使胃癌细胞凋亡，对人胃癌细胞具有较强的抑制作用。
红芪：甘，温。归肺、脾经。补气固表，利尿托毒，排脓，敛疮生肌。红芪能显著提高巨噬细胞吞噬指数与E-花环形成率，有提高非特异性免疫力与细胞免疫力的作用。对胃癌细胞具有抑制增殖、G2/M期阻滞和诱导凋亡作用。
野菊花：苦、辛，微寒。归肝、心经。清热解毒。对胃癌细胞的生长有明显的抑制作用，具有直接细胞毒作用。
菝葜：甘、酸，平。祛风利湿，解毒消肿。菝葜对胃癌疗效较好。具有增进食欲、减少呕吐、疏通狭窄食管，以及利尿消肿、增强体力、提高红细胞及血红蛋白，和一定的止痛安眠作用。
银杏叶：甘、苦、涩，平；有毒。归肺经。敛肺定喘，止带浊，缩小便。银杏能抑制胃癌细胞增殖并阻抑细胞周期进程，诱导其凋亡。
大蒜素：大蒜素对人胃癌细胞株增殖具有明显抑制作用,使受损伤细胞阻滞于细胞Gz/M期,增加损伤DNA修复,减少染色体畸变,使受损细胞不产生异常增殖。
黄莲：苦，寒。归心、脾、胃、肝、胆、大肠经。清热燥湿，泻火解毒。黄连素可诱导胃癌细胞凋亡并将胃癌细胞阻滞在G0～G1期,还具有抗肿瘤转移作用。
白果槲寄生：甘；苦；性平祛风湿；强筋骨；催乳。白果槲寄生胃癌有很好疗效，适用于不能手术的晚期胃癌患者，可延长生命，明显缓解疼痛，缓解病程，甚至对极严重的病例也很少需要常规地使用止痛药。槲寄生还具有明显的抑制肿瘤细胞转移的作用。
本发明是由中国传统的中草药制成，根据中医辨证论治及现代医学的若干原则，以某些成分确定、功效明晰的天然提取物的有序配伍，组合成了有诱导胃癌细胞凋亡与促使其分化的中药。
本发明既有化学治疗之功，又平和无毒，可谓“零毒化疗”。 用药多年来，患者无任何不良反应，跟踪血液检查正常，且疗效不反弹。5年生存率大幅提高。
本发明可以使各中药成分在发挥其抗癌作用的同时相互协同，相辅相成，可以起到相互促进的作用，既能抑制胃癌细胞的增值，又能杀死胃癌细胞诱导胃癌细胞凋亡，起到治疗胃癌的作用。本发明与手术治疗相结合可以促进患者康复，预防术后肿瘤的复发和转移，快速帮助患者康复。
本发明能够帮助晚期胃癌患者改善症状、减轻痛苦、提高病人生存质量。对于已复发或转移及无法进行西医手术、放化疗治疗的患者，通过单独服用本配方中药，增强机体免疫功能，诱导胃癌细胞分化和凋亡，也可以达到延长病人生命的作用，甚至有可能带瘤生存。
本发明所述的中药组合物可用于治疗胃癌，具有显著疗效。本发明治疗费用相对低廉，远远低于西医的治疗费用。
本发明的中药组合物原料易得，工艺简单，成本低，效率高，有利于制药企业进行药品生产、质量控制；产品价格低，易于被患者接受。
本发明还提供了一种由上述治疗该病的中药组合物制成的口服制剂，所述口服制剂包括口服液、片剂、胶囊剂、丸剂等，优选剂型为口服液和胶囊剂，一日一剂，分早晚两次服用。
本发明的中药组合物可以制备成多种剂型。例如，将煎煮后的药液杀菌消毒后装袋，制成口服液；或者将煎煮后的药液进行浓缩，烘干后，加入医学上可接收的辅料，然后制成片剂、胶囊剂、丸剂等。
所述医学上可接收的辅料包括淀粉、糊精、羧甲基纤维素钠、聚乙二醇、磷酸氢钙、海藻酸钠、山梨酸钾等。
以上所述，仅是本发明的较佳实施例而已，并非对本发明作任何形式上的限制，本领域技术人员利用上述揭示的技术内容做出些许简单修改、等同变化或修饰，均落在本发明的保护范围内。
Claims (4)
1.一种治疗胃癌的中药，其特征是由下列重量份的原料药组成：大蒜素0.05～0.1重量份；高良姜、黄莲3～6重量份；山柰、银杏叶4.5～9重量份；连翘7～15重量份；野菊花9～18重量份；红芪、菝葜、白果槲寄生15～30重量份；金荞麦根20～40重量份。
2.根据权利要求1所述的一种治疗胃癌的中药，其特征是由下列重量份的原料药组成：大蒜素0.1重量份；高良姜、黄莲3～6重量份；山柰、银杏叶9重量份；连翘15重量份；野菊花18重量份；红芪、菝葜、白果槲寄生30重量份；金荞麦根40重量份。
3.一种治疗胃癌的口服制剂，其特征是由权利要求1或2中任一项所述的中药组合物制成。
4.根据权利要求3所述的一种治疗胃癌的口服制剂，其特征是，所述口服制剂包括口服液、片剂、胶囊剂、丸剂，优选口服液和片剂。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010820710.4A CN112426499A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗胃癌的中药组合物 |
| CN2020108207104 | 2020-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113368205A true CN113368205A (zh) | 2021-09-10 |
Family
ID=74690359
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010820710.4A Pending CN112426499A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗胃癌的中药组合物 |
| CN202110746322.0A Pending CN113368205A (zh) | 2020-08-15 | 2021-07-02 | 一种治疗胃癌的中药组合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010820710.4A Pending CN112426499A (zh) | 2020-08-15 | 2020-08-15 | 一种治疗胃癌的中药组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN112426499A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113209201A (zh) * | 2020-08-15 | 2021-08-06 | 仲崇允 | 一种治疗各种癌症的中药组合物 |
-
2020
- 2020-08-15 CN CN202010820710.4A patent/CN112426499A/zh active Pending
-
2021
- 2021-07-02 CN CN202110746322.0A patent/CN113368205A/zh active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113209201A (zh) * | 2020-08-15 | 2021-08-06 | 仲崇允 | 一种治疗各种癌症的中药组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112426499A (zh) | 2021-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106361993A (zh) | 一种防治胃黏膜损伤的药物组合物及其制备方法 | |
| CN113368205A (zh) | 一种治疗胃癌的中药组合物 | |
| CN112546111A (zh) | 一种治疗化疗相关性腹泻的中药贴剂及其制备方法 | |
| WO2020042665A1 (zh) | 一种鲨鱼软骨糖蛋白及其抗癌用途 | |
| CN113304226A (zh) | 一种治疗肺癌的中药组合物 | |
| CN102940808A (zh) | 一种用于治疗肺癌的组方药物及制备方法 | |
| CN104383519A (zh) | 一种治疗胃癌的中西药组合物及其制备方法 | |
| CN100406026C (zh) | 一种治疗慢性胃炎、胃癌的药物及其制备方法 | |
| CN103735745B (zh) | 一种治疗肺部肿瘤的中药制剂及制备方法 | |
| CN112426469A (zh) | 一种治疗艾氏腹水癌的中药组合物 | |
| CN112426491A (zh) | 一种治疗恶性黑色素瘤的中药组合物 | |
| CN112426500A (zh) | 一种治疗宫颈癌的中药组合物 | |
| CN115154576B (zh) | 一种治疗恶性肿瘤相关性腹泻的中药组合物 | |
| CN112426465A (zh) | 一种治疗鼻咽癌、鳞状细胞癌的中药组合物 | |
| CN112316071A (zh) | 一种治疗肝癌的中药组合物 | |
| CN112426478A (zh) | 一种治疗肠癌的中药组合物 | |
| CN102836276A (zh) | 治疗骨性关节炎的骨刺软化丸 | |
| CN111714601A (zh) | 一种治疗真菌感染的中药组合物 | |
| CN112426475A (zh) | 一种治疗淋巴细胞白血病的中药组合物 | |
| CN112426486A (zh) | 一种治疗早幼粒细胞白血病的中药组合物 | |
| CN112426466A (zh) | 一种治疗各种癌症的中药组合物 | |
| CN106938031A (zh) | 一种甲状腺瘤的治疗药物 | |
| CN111759946A (zh) | 一种治疗疝气的中药组合物 | |
| CN113648391A (zh) | 一种治疗白血病的中药组合物 | |
| CN112245518A (zh) | 一种治疗粒细胞型白血病的中药组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210910 |